PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation.
PD-L1
cell block
fixation
immunotherapy
lung cancer
pre-analytical
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
21
02
2020
revised:
03
04
2020
accepted:
07
04
2020
pubmed:
26
4
2020
medline:
16
3
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
In the selection of non-small cell lung cancer (NSCLC) patients for immunotherapy, specimen processed as cell blocks (CBs) may be the only available material to assess PD-L1 expression. Therefore, optimal CB preparation becomes paramount. In this context, here we assessed whether inadequate fixation time might be one of the pre-analytical factors affecting PD-L1 expression. Ex vivo CBs from placental (n = 3) and NSCLC (n = 8) resection specimens were obtained. PD-L1 staining was performed on CBs prepared at increasing fixation times (12 hours, 48 hours, 72 hours, 96 hours, 168 hours and 504 hours) using the companion diagnostic SP263 Assay and a validated 22C3 laboratory developed test (LDT). Staining intensity and percentage of positive cells were evaluated. All placental CBs showed moderate to strong PD-L1 positivity in most cells, regardless of the fixation time. Likewise, the percentage of SP263-stained NSCLC cells was similar at all fixation times except for one case, which showed less intense SP263 staining at 168 hours. Conversely, in 5/8 cases, the 22C3 LDT percentage of positive cells and staining intensity decreased at 168 hours and 504 hours. Our results show that fixation time influences the performance of 22C3 LDT on CBs. Thus, we recommend that the fixation time of cytological materials be carefully checked, especially when PD-L1 testing is delayed until the oncology request. Indeed, delays in tissue processing and paraffin embedding may lead to sub-optimal performance of PD-L1 staining on CBs.
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-603Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Mino-Kenudson M, Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med. 2016;13(2):157-170.
Kowanetz M, Zou W, Gettinger SN, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018;115(43):E10119-E10126. https://doi.org/10.1073/pnas.1802166115.
Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for Pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol AIMM. 2016;24(6):392-397.
Dolled-Filhart M, Roach C, Lubiniecki GM, Ponto G, Emancipator K. Development of a companion diagnostic for Pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death Ligand-1. Arch Pathol Lab Med. 2016;140:1243-1249. https://doi.org/10.5858/arpa.2015-0542-OA.
Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302-1311.
Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, PA VL. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol. 2018;7(3):133-141.
Stoy SP, Rosen L, Mueller J, Murgu S. Programmed Death-Ligand 1 Testing of Lung Cancer Cytology Specimens Obtained with Bronchoscopy. Cancer Cytopathol. 2018;126:122-128.
Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. Cancer Cytopathol. 2019;127:447-457.
Xu H, Bratton L, Nead M, Russell D, Zhou Z. Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. Cytojournal. 2018;15(1):29.
Lozano MD, Abengozar-Muela M, Echeveste JI, et al. Programmed death-ligand 1 expression on direct pap-stained cytology smears from non-small cell lung cancer: comparison with cell blocks and surgical resection specimens. Cancer Cytopathol. 2019;127(7):470-480.
Skov B, Skov T. P2.01-048 paired comparison of PDL1 assessment on cytology and histology from malignancies in the lung. J Thorac Oncol. 2017;12(1):S815.
Pak MG, Roh MS. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: comparison of cell-blocks and matched surgical resection specimens in lung cancer. Cytopathology. 2019;30:578-585. https://doi.org/10.1111/cyt.12743.
Noll B, Wang W-L, Gong Y, et al. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathol. 2018;126:342-352. https://doi.org/10.1002/cncy.21987.
Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P. Use of the 22C3 anti-programmed death ligand 1 antibody to determine programmed death ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Cancer Cytopathol. 2018;126:264-274.
Humphries MP, Mcquaid S, Craig S, et al. Critical appraisal of PD-L1 reflex diagnostic testing: current standards and future opportunities. J Thorac Oncol. 2019;14:45-53.
Heymann JJ, Bulman WA, Swinarski D, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017;125(12):896-907.
Evans M, O'Sullivan B, Hughes F, et al. The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay. Pathol Oncol Res. 2020;26:79-89. https://doi.org/10.1007/s12253-018-0469-6.
Wang H, Agulnik J, Kasymjanova G, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol. 2018;29:1417-1422.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
Van Seijen M, Brcic L, Gonzales AN, Sansano I, Bendek M, et al. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch. 2019;475:191-199. https://doi.org/10.1007/s00428-019-02595-9.
Gosney JR, Haragan A, Chadwick C, et al. Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation? Cancer Cytopathol. 2020;128:100-106. https://doi.org/10.1002/cncy.22216.
Vigliar E, Malapelle U, Iaccarino A, et al. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. J Clin Pathol. 2019;72(6):412-417.
Malapelle U, Bellevicine C, Russo A, Salatiello M, Palombini L, Troncone G. KRAS testing on colo-rectal carcinoma cytological imprints. Diagn Cytopathol. 2011;39(4):274-277. https://doi.org/10.1002/dc.21417.
Treece AL, Montgomery ND, Patel NM, Civalier CJ, Dodd LG, Gulley ML, et al. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas. Cancer Cytopathol [Internet]. 2016;124(6):406-414.
Gleeson FC, Kipp BR, Levy MJ, et al. Lung cancer adrenal gland metastasis: Optimal fine-needle aspirate and touch preparation smear cellularity characteristics for successful theranostic next-generation sequencing. Cancer Cytopathol. 2014;122(11):822-832. https://doi.org/10.1002/cncy.21464.
Mainini V, Pagni F, Garancini M, Giardini V, De Sio G, Cusi C, et al. An alternative approach in endocrine pathology research: MALDI-IMS in papillary thyroid carcinoma. Vol. 24, Endocrine Pathology; 2013. pp. 250-253.
Thunnissen E, Kerr KM, Herth FJF, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Vol. 76, Lung Cancer; 2012. pp. 1-18.
Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681-1690.
Engel KB, Moore HM. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med. 2011;135(5):537-543.
Nambirajan A, Jain D. Cell blocks in cytopathology: an update. Cytopathology. 2018;29(6):505-524. https://doi.org/10.1111/cyt.12627.
Lloyd IE, Zhou W, Witt BL, Chadwick BE. Characterization of PD-L1 immunohistochemical expression in cell blocks with different specimen fixation and processing methods. Appl Immunohistochem Mol Morphol. 2019;27(2):107-113.
Crapanzano J, Heymann J, Monaco S, Nassar A, Saqi A. The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicine. Cytojournal. 2014;11(1):7.
Thunnissen E, de Langen AJ, Smit EF. PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer. 2017;113:102-105.
Tsao MS, Kerr KM, Yatabe Y, Hirsch FR. International Association for the Study of Lung Cancer Edited by IASLC ATLAS of PD-L1 Immunohistochemistry Testing in Lung Cancer Conquering Thoracic Cancers Worldwide.
Cheung CC, Barnes P, Bigras G, et al. Fit-for-purpose PD-L1 biomarker testing for patient selection in Immuno-oncology: guidelines for clinical laboratories from the Canadian Association of Pathologists-Association Canadienne des Pathologistes (CAP-ACP). Appl Immunohistochem Mol Morphol. 2019;27(10):699-714.